Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMNKBEC)

Drug Name
Infigratinib Drug Info
Synonyms BGJ398
Indication
Disease Entry ICD 11 Status REF
Cholangiocarcinoma 2C12.10 Approved [1]
Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
Cross-matching ID
PubChem CID
53235510
ChEBI ID
CHEBI:63451
CAS Number
CAS 872511-34-7
TTD Drug ID
DMNKBEC

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fibroblast growth factor receptor (FGFR) TT0LF7H NOUNIPROTAC Inhibitor [3]
Fibroblast growth factor receptor 1 (FGFR1) TTRLW2X FGFR1_HUMAN Modulator [4]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Fibroblast growth factor receptor 1 (FGFR1) DTT FGFR1 5.32 6.548 5.908 6.126
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Cholangiocarcinoma
ICD Disease Classification 2C12.10
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Fibroblast growth factor receptor 1 (FGFR1) DTT FGFR1 4.79E-02 -0.03 -0.15
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 FDA Approved Drug Products from FDA Official Website. 2021. Application Number: 214622.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7877).
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res. 2013 Apr;28(4):899-911.